Windtree Therapeutics Inc (WINT) concluded trading on Thursday at a closing price of $0.20, with 8.99 million shares of worth about $1.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -94.39% during that period and on January 23, 2025 the price saw a gain of about 0.25%. Currently the company’s common shares owned by public are about 11.05M shares, out of which, 10.99M shares are available for trading.
Stock saw a price change of -17.08% in past 5 days and over the past one month there was a price change of -38.00%. Year-to-date (YTD), WINT shares are showing a performance of -42.31% which decreased to -97.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $14.75 during that period. The average intraday trading volume for Windtree Therapeutics Inc shares is 2.05 million. The stock is currently trading -26.95% below its 20-day simple moving average (SMA20), while that difference is down -47.95% for SMA50 and it goes to -94.17% lower than SMA200.
Windtree Therapeutics Inc (NASDAQ: WINT) currently have 11.05M outstanding shares and institutions hold larger chunk of about 1.48% of that.
The stock has a current market capitalization of $2.23M and its 3Y-monthly beta is at 0.54. It has posted earnings per share of -$18.63 in the same period. It has Quick Ratio of 0.27 while making debt-to-equity ratio of 1.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for WINT, volatility over the week remained 12.81% while standing at 12.45% over the month.
Analysts are in expectations that Windtree Therapeutics Inc (WINT) stock would likely to be making an EPS of -0.92 in the current quarter, while forecast for next quarter EPS is 0 and it is -2.86 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.92 which is -0.92 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -13.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 94.00% while it is estimated to increase by 49.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on June 26, 2020 offering a Buy rating for the stock and assigned a target price of $12.25 to it.
